SLU-PP-332, a novel ERR agonist, demonstrates potential as an exercise mimetic by enhancing mitochondrial function and metabolic health. Despite its promise, further research is required to fully understand the pharmacokinetics and safety profile [PMID: 41850449, PMID: 41688415].
SLU-PP-332, a novel ERR agonist, demonstrates potential as an exercise mimetic by enhancing mitochondrial function and metabolic health. Despite its promise, further research is required to fully understand the pharmacokinetics and safety profile [PMID: 41850449, PMID: 41688415].
• SLU-PP-332 enhances mitochondrial function and metabolic health [PMID: 41688415]. • Identified in in vitro studies as a potential doping concern due to exercise mimicry [PMID: 41588687]. • Promotes fat oxidation and energy expenditure in mouse models [PMID: 41688415]. • Advances understanding of ERR signaling and exercise-responsive pathways [PMID: 41850449].
SLU-PP-332, an agonist of the estrogen-related receptors (ERRα/β/γ), is receiving significant attention for its potential as an exercise mimetic. This compound targets ERRs, orphan nuclear receptors crucial for regulating mitochondrial metabolism and other exercise-related genes [PMID: 41688415]. Given the intricate role of ERRs in skeletal muscle adaptation, SLU-PP-332 offers a promising therapeutic approach for metabolic diseases and muscle atrophy associated with inactivity [PMID: 40692696].
Research has shown that SLU-PP-332 can mimic the physiological effects of exercise, including the promotion of oxidative muscle fibers and fatty acid oxidation, while increasing exercise endurance in laboratory settings. In mouse models, SLU-PP-332 enhanced energy expenditure and insulin sensitivity, contributing to its promise as a therapeutic agent for conditions like obesity and type 2 diabetes [PMID: 41688415]. Through structure-activity relationship (SAR) studies, significant insights have been gained into the molecular mechanisms through which SLU-PP-332 influences ERR signaling. Key structural determinants have been identified, providing a foundation for the development of next-generation therapeutics [PMID: 41850449].
Detailed metabolic investigations have identified various transformation products of SLU-PP-332. In vitro studies using human liver microsomes exposed nine metabolites, with specific transformations indicating potential metabolic pathways that can aid in future doping control measures [PMID: 41588687]. These metabolites' identification is crucial as SLU-PP-332 is also considered in the realm of sports doping, given its capability to mimic exercise responses [PMID: 41688415].
Despite its potential, SLU-PP-332 requires further clinical investigation to fully determine its pharmacokinetic profile and long-term safety. Current studies have largely been laboratory-based or using animal models, with human applications yet to be exhaustively explored. The compound’s lack of oral bioavailability necessitates alternatives such as SLU-PP-915, which shows promise but represents a different chemical approach [PMID: 41421047]. As research progresses, understanding the exact effects of SLU-PP-332 on human metabolism and muscle function will be crucial, with significant implications for addressing conditions like sarcopenia and metabolic syndrome [PMID: 40692696].
This research briefing is based on the verified PubMed records linked in the References & Citations section below.
Ask PepBot any follow-up question about this topic. It knows every study, every protocol, every dosing detail.
Send this cited research summary to someone who is asking the same question.
Keep exploring
Mechanism, study context, and related research for SLU-PP-332
Mechanism, study context, and related research for SLU-PP-915
Browse every ChatPEP research guide
See side-by-side research comparisons